Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian C Shaffer

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|August 24, 2023
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantationShlomo Elias, Samantha Brown, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic MalignanciesSatyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2017
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Satyajit Kosuri, et al.
Transplantation and Cellular Therapy|July 6, 2025
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRAntonio M Jimenez Jimenez, Stephen R Spellman, Ioannis Politikos, et al.
Blood Advances|March 6, 2025
Transplant Outcomes Using Older Matched Sibling Donors Compared to Young Alternative Donors: A CIBMTR AnalysisKarthik Nath, Mei-Jie Zhang, Matthew Bye, et al.
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
The Lancet. Haematology|December 3, 2025
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 studyMichael Scordo, Miguel-Angel Perales, Audrey Mauguen, et al.
Transplantation and Cellular Therapy|April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 AlterationsMoataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Transplantation and Cellular Therapy|May 25, 2021
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular TherapyCorrado Zuanelli Brambilla, Stephanie M Lobaugh, Josel D Ruiz, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|August 24, 2023
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantationShlomo Elias, Samantha Brown, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic MalignanciesSatyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2017
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Satyajit Kosuri, et al.
Transplantation and Cellular Therapy|July 6, 2025
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRAntonio M Jimenez Jimenez, Stephen R Spellman, Ioannis Politikos, et al.
Blood Advances|March 6, 2025
Transplant Outcomes Using Older Matched Sibling Donors Compared to Young Alternative Donors: A CIBMTR AnalysisKarthik Nath, Mei-Jie Zhang, Matthew Bye, et al.
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
The Lancet. Haematology|December 3, 2025
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 studyMichael Scordo, Miguel-Angel Perales, Audrey Mauguen, et al.
Transplantation and Cellular Therapy|April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 AlterationsMoataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Transplantation and Cellular Therapy|May 25, 2021
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular TherapyCorrado Zuanelli Brambilla, Stephanie M Lobaugh, Josel D Ruiz, et al.
Pageof 8